IN2014DN00195A - - Google Patents

Info

Publication number
IN2014DN00195A
IN2014DN00195A IN195DEN2014A IN2014DN00195A IN 2014DN00195 A IN2014DN00195 A IN 2014DN00195A IN 195DEN2014 A IN195DEN2014 A IN 195DEN2014A IN 2014DN00195 A IN2014DN00195 A IN 2014DN00195A
Authority
IN
India
Application number
Inventor
Md Mohammad Nezami
Original Assignee
Res Cancer Inst Of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Cancer Inst Of America filed Critical Res Cancer Inst Of America
Publication of IN2014DN00195A publication Critical patent/IN2014DN00195A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
IN195DEN2014 2011-07-07 2014-01-09 IN2014DN00195A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505393P 2011-07-07 2011-07-07
US201161507950P 2011-07-14 2011-07-14
PCT/US2012/045821 WO2013006821A1 (en) 2011-07-07 2012-07-06 Systems, methods, and formulations for treating cancer

Publications (1)

Publication Number Publication Date
IN2014DN00195A true IN2014DN00195A (en) 2015-06-05

Family

ID=47437478

Family Applications (1)

Application Number Title Priority Date Filing Date
IN195DEN2014 IN2014DN00195A (en) 2011-07-07 2014-01-09

Country Status (13)

Country Link
US (3) US20130011488A1 (en)
EP (2) EP2729008B1 (en)
JP (3) JP6082737B2 (en)
KR (2) KR102020939B1 (en)
CN (2) CN109675041A (en)
AU (2) AU2012278813B2 (en)
CA (1) CA2839727C (en)
ES (1) ES2630306T3 (en)
IN (1) IN2014DN00195A (en)
MX (1) MX354383B (en)
PL (1) PL2729008T3 (en)
RU (1) RU2644635C2 (en)
WO (1) WO2013006821A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
CA2861047A1 (en) * 2012-01-18 2013-07-25 Concert Pharmaceuticals, Inc. Deuterated alpha-lipoic acid
CN103877066B (en) * 2014-02-21 2016-08-24 中国人民解放军第二军医大学 Carry preparation method and the application of the self-assembled nanometer grain of docetaxel and sulforaphane
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) * 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
EP3691632A4 (en) * 2017-10-06 2021-05-26 Research Cancer Institute of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US20220111019A1 (en) * 2018-09-19 2022-04-14 Virginia Tech Intellectual Properties, Inc. Brca1 modulating compounds, formulations thereof, and uses thereof
WO2021119298A1 (en) * 2019-12-10 2021-06-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapies for the treatment of cancer
CN112336716A (en) * 2020-11-25 2021-02-09 四川大学华西医院 Application of vitamin C and disulfiram in preparation of anti-tumor combined medicine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569836A (en) * 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
JP2514500B2 (en) * 1991-09-14 1996-07-10 呉羽化学工業株式会社 Multidrug resistance inhibitor and expression inhibitor
EP0896544B1 (en) * 1996-06-11 2003-02-26 Novartis AG Combination of a somatostatin analogue and a rapamycin
US5865722A (en) 1997-04-04 1999-02-02 Numotech, Incorporated Shape-adaptable topical hyperbaric oxygen chamber
US6299925B1 (en) * 1999-06-29 2001-10-09 Xel Herbaceuticals, Inc. Effervescent green tea extract formulation
US6376525B1 (en) * 2000-09-15 2002-04-23 Qingzhong Kong Method and composition for treating cancer using cellular organelle crystallizing agents
JP2004528278A (en) * 2000-12-18 2004-09-16 ボード オブ レジェンツ,ザ ユニバーシティー オブ テキサス システム Localized area chemotherapy and radiation treatment using in situ hydrogel
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US6572897B1 (en) * 2002-07-03 2003-06-03 Vitacost.Com, Inc. Insulin sensitivity maintenance and blood sugar level maintenance formulation for the prevention and treatment of diabetes
US20070190022A1 (en) * 2003-08-29 2007-08-16 Bacopoulos Nicholas G Combination methods of treating cancer
EP1571225A1 (en) * 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
EP1799759A1 (en) * 2004-08-30 2007-06-27 Lunamed Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
JP2006298781A (en) * 2005-04-15 2006-11-02 Geno Membrane:Kk Estrone-3-sulfate transporter activity inhibitor
ES2444890T3 (en) * 2006-03-31 2014-02-27 Erasmus University Medical Center Rotterdam New composition for tumor growth control
EP1847274A1 (en) * 2006-04-21 2007-10-24 CIPROSA LLC - Corporate Creations Network, Inc. Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy
EP2040708B1 (en) * 2006-07-17 2018-03-14 Thomas Christian Lines Quercetin-containing compositions
JP2010514777A (en) * 2006-12-26 2010-05-06 ファーマサイクリックス,インク. Methods for monitoring biomarkers using histone deacetylase inhibitors in combination therapy
US20080305096A1 (en) * 2007-06-07 2008-12-11 Unicity International, Inc. Method and composition for providing controlled delivery of biologically active substances
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
US8394377B2 (en) * 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
US20110118309A1 (en) * 2008-07-18 2011-05-19 Peter Wisdom Atadja Use of hdac inhibitors for the treatment of hodgkin's disease
US20100316733A1 (en) * 2009-06-15 2010-12-16 Locklear Kenneth R Hyperbaric Oxygen Therapy and Treatment Method

Also Published As

Publication number Publication date
AU2016269491A1 (en) 2017-01-05
RU2014101261A (en) 2015-08-20
AU2012278813A1 (en) 2014-01-30
WO2013006821A1 (en) 2013-01-10
PL2729008T3 (en) 2017-10-31
CA2839727C (en) 2023-10-17
AU2016269491B2 (en) 2018-08-30
US20130011488A1 (en) 2013-01-10
US20200206183A1 (en) 2020-07-02
MX2014000150A (en) 2014-05-14
AU2012278813B2 (en) 2016-09-08
KR102020939B1 (en) 2019-09-11
JP6401317B2 (en) 2018-10-10
RU2644635C2 (en) 2018-02-13
JP2017105797A (en) 2017-06-15
KR20190107166A (en) 2019-09-18
CA2839727A1 (en) 2013-01-10
EP3326625A1 (en) 2018-05-30
CN109675041A (en) 2019-04-26
US20170014376A1 (en) 2017-01-19
ES2630306T3 (en) 2017-08-21
JP2018203767A (en) 2018-12-27
EP2729008B1 (en) 2017-04-05
JP6082737B2 (en) 2017-02-15
EP2729008A4 (en) 2014-10-29
CN103796514A (en) 2014-05-14
KR20140076546A (en) 2014-06-20
MX354383B (en) 2018-03-02
JP2014518274A (en) 2014-07-28
EP2729008A1 (en) 2014-05-14

Similar Documents

Publication Publication Date Title
AP3853A (en)
BR112013031251A2 (en)
BR112013027245A2 (en)
BR112013026905A2 (en)
BR112013017670A2 (en)
BR112013028733A2 (en)
BR112013027121A2 (en)
BR112013027452A2 (en)
AP2016009466A0 (en)
BR112013031556A2 (en)
BR112013032377A2 (en)
BR112013032380A2 (en)
BR112013032366A2 (en)
BR112013026895A2 (en)
BR112013027761A2 (en)
BR112013027836A2 (en)
BR112013032392A2 (en)
IN2014DN00195A (en)
BR112013027871A2 (en)
BR112013030734A2 (en)
BR112013032394A2 (en)
BR112013027657A2 (en)
BR112013027112A2 (en)
AP3777A (en)
AP3936A (en)